No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Dosage form

Tablets with modified release, coated


1 pill contains Trimetazidine dihydrochloride 35 mg;
Excipients: Calcium hydrogen phosphate dihydrate, microcrystalline cellulose, colloidal silicon dioxide (aerosil), hydroxypropylcellulose Klucel LF, hydroxypropylmethylcellulose, plasdone S-630, Magnesium stearate;
shell composition: Selyokout (hydroxypropylmethylcellulose, Plasdone S-630, polyethylene glycol, talc, iron oxide red, titanium dioxide)


30 pieces

Mechanism of action

Deprenorm MB is an antianginal medication that improves myocardial metabolism. It has antihypoxic and antianginal effects.

Directly improves the metabolism and function of cardiomyocytes and brain neurons. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (due to increased aerobic glycolysis and inhibition of fatty acid oxidation). Supports normal myocardial contractility, prevents intracellular depletion of ATP and creatine phosphate. Under conditions of acidosis, it normalizes the state of the ion channels of the membranes, prevents the accumulation of calcium and sodium in cardiomyocytes,normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, increases the duration of electrical potential, prevents activation of neutrophils in the ischemic area, reduces the release of CPK from cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks and reduces the need for nitrates. After 2 weeks of treatment, exercise tolerance increases, and blood pressure drops are reduced. On the background of the use of the drug, hearing and results of vestibular tests are improved, dizziness and tinnitus are reduced. With vascular pathology of the eye, the functional state of the retina is improved.

Indications and usage

  • IHD: prevention of strokes (as part of complex therapy);
  • chorioretinal vascular disorders;
  • vertigo of vascular origin;
  • cochleo-vestibular disorders of the ischemic nature (tinnitus, hearing impairment).


  • renal failure (CC <15 ml / min);
  • severe liver dysfunction;
  • children and adolescents under 18 years of age (efficacy and safety have not been established);
  • pregnancy;
  • lactation (breastfeeding);
  • Hypersensitivity to the components of the drug Deprenorm.

Dosage and administration

Deprenorm MB is prescribed orally at a dose of 70 mg / day (2 tablets) in 2 divided doses. The duration of treatment is set individually.
Tablets are taken with meals.

Adverse reactions

Gastrointestinal: rarely - gastralgia, nausea, vomiting.
Allergic reactions: pruritus
Other: headache, feeling of palpitations.

Deprenorm MB is not intended to relieve angina attacks. With the development of attacks of angina pectoris should be reviewed current therapy.

Influence on ability to drive motor transport and control mechanisms
Trimetazide does not affect the ability to drive a car and perform work that requires high-speed psychomotor reactions.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 ° C.

Deprenorm mv

34 Items